NCT04983745

Niraparib and Dostarlimab in HRD Solid Tumors

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: West Cancer Center · Academic / Other
• Sex: All
• Age: 100 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic homologous recombination deficiency (HRD) gene mutation

Conditions

• Homologous Recombination Deficient Solid Tumors

Interventions

Type	Name	Description
DRUG	Combination drug	niraparib and dostarlimab combination

Timeline

• Start date: 2021-11-29
• Primary completion: 2024-08-01
• Completion: 2025-08-01
• First posted: 2021-07-30
• Last updated: 2023-12-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study